A team of cancer imaging experts at Johns Hopkins has embarked on a five-year research initiative to speed development of early diagnostic tests and new treatments for breast, prostate and other common cancers.
Using advanced imaging tools developed or used for the last decade at Johns Hopkins In-Vivo Cellular and Molecular Imaging Center (ICMIC), the team will search for innovative ways to detect cancers in their earliest stages inside cells, and for ways to stop or kill any of these cancer cells before the disease can spread to other tissues and organs.
“Our next round of studies are aimed at turning what we’ve shown to be feasible into clinical reality,” says cancer imaging researcher Zaver Bhujwalla, Ph.D., who will act as the principal investigator of the expanded initiative. The expansion is made possible with more than $8 million in new grants from the U.S. National Cancer Institute, a member of the National Institutes of Health.
Read more at: http://www.newswise.com/articles/view/584336/?sc=mwhr&xy=10006693
Source: Newswise; Johns Hopkins Medicine
Legal Navigation Services Key to Addressing Disparities in Cancer Care
July 31st 2025A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More